Table 2.

Summary of imatinib mesylate efficacy in patients with locally advanced or recurrent diffuse-type TGCT.

Parameter	Patients N (%)
RECIST best response*
Complete remission	2 (4)
Partial response	15 (27)
Stable disease	36 (65)
Progressive disease	2 (4)
Overall response rate	17 (31)
Rate of disease control	53 (96)
Symptomatic response	40 (78)**
Median IM treatment duration (IQR), mo.	9.3 (5–26)
Median PFS (IQR), mo.	18 (8–55)

Abbreviations: TGCT = Tenosynovial Giant Cell tumour, IM = imatinib mesylate, N = Number of patients, mo = months, yrs = years, IQR = inter quartile range.

Overall response rate includes complete remission and partial response; Rate of disease control includes complete remission, partial response and stable disease; Symptomatic response was indicated as present or not (40/51 = 78%). Metastatic patients (n = 4) were excluded.

*N = 3 RECIST best response not available; **N = 9 symptomatic response not available.